Suppr超能文献

具有胃滞留性能的阿昔洛韦的粘膜粘附型漂浮空心珠的研制。

Development of mucoadhesive floating hollow beads of acyclovir with gastroretentive properties.

机构信息

School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland , Auckland , New Zealand.

出版信息

Pharm Dev Technol. 2014 Aug;19(5):571-6. doi: 10.3109/10837450.2013.813539. Epub 2013 Jul 17.

Abstract

This study aimed at improving the oral bioavailability of acyclovir (ACV) through incorporating it into gastroretentive dosage form based on floating hollow chitosan beads. Hollow chitosan beads were prepared using a solvent free, ionotropic gelation method. The effect of formulation parameters, including chitosan molecular weight and drug concentration, on bead characteristics was studied. The drug containing formulations had yields >70.5 ± 0.31%. The entrapment efficiencies for the medium molecular weight chitosan formulations (56.29 ± 0.94%-62.75 ± 0.86%) was greater than the high molecular weight chitosan formulation (29.21 ± 0.89%). The density of all formulations was below that of gastric fluid, the greatest density observed was 0.60 ± 0.01 g cm(-3). Unsurprisingly, the formulations were immediate bouyant to different degrees in both pH 1.2 and pH 6.8 media. In addition, the chitosan beads were all seen to swell in pH 1.2 media and demonstrated mucoadhesive properties. A sustained release profile was observed from the chitosan beads, the developed formulations released drug at slower rates than a marketed ACV oral tablet. The developed system has the dual advantages of being gastroretentive, to increase oral bioavailability and releasing drug in a controlled manner, to reduce the required frequency of administration thereby promoting patient adherence.

摘要

本研究旨在通过将阿昔洛韦(ACV)制成基于漂浮中空壳聚糖珠的胃滞留剂型来提高其口服生物利用度。中空壳聚糖珠是使用无溶剂、离子凝胶化方法制备的。研究了制剂参数(包括壳聚糖分子量和药物浓度)对珠粒特性的影响。载药制剂的产率>70.5±0.31%。中分子量壳聚糖制剂(56.29±0.94%-62.75±0.86%)的包封效率大于高分子量壳聚糖制剂(29.21±0.89%)。所有制剂的密度均低于胃液密度,观察到的最大密度为 0.60±0.01g/cm(-3)。不出所料,在 pH 1.2 和 pH 6.8 介质中,这些制剂都不同程度地立即漂浮。此外,壳聚糖珠在 pH 1.2 介质中均可见膨胀,并表现出黏膜黏附特性。壳聚糖珠呈现出持续释放的特征,所开发的制剂比市售的 ACV 口服片剂释放药物的速度更慢。该开发系统具有双重优势,即胃滞留以提高口服生物利用度和以控制方式释放药物,从而减少所需的给药频率,提高患者的依从性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验